CymaBay Therapeutics Inc. (NASDAQ:CBAY) traded down 3.2% during trading on Wednesday . The company traded as low as $2.40 and last traded at $2.41, with a volume of 79,875 shares traded. The stock had previously closed at $2.49.

A number of equities research analysts have commented on the stock. Zacks Investment Research raised shares of CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 12th. HC Wainwright reaffirmed a “buy” rating on shares of CymaBay Therapeutics in a research report on Thursday, May 12th. Finally, Roth Capital assumed coverage on shares of CymaBay Therapeutics in a research report on Friday, July 1st. They set a “buy” rating for the company.

The stock’s 50 day moving average price is $1.98 and its 200 day moving average price is $1.84. The firm’s market capitalization is $56.51 million.

CymaBay Therapeutics (NASDAQ:CBAY) last released its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.32) by $0.02. On average, analysts forecast that CymaBay Therapeutics Inc. will post ($1.20) earnings per share for the current year.

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.